



ABN 53 075 582 740

BIONOMICS LIMITED

ASX Results Announcement, Directors' Report and Financial Statements – 30 June 2017

Lodged with the ASX under Listing Rule 4.3A

Contents

Results for Announcement to the Market & Supplementary Information	2
Announcement	3
Attachment - Directors' Report and Audited Financial Statements	

BIONOMICS LIMITED

Year ended 30 June 2017

(previous corresponding period: year ended 30 June 2016)

Results for Announcement to the Market

				\$
Cash and cash equivalents as at 30 June 2017 from 30 June 2016	decreased by	5.67%	to	42,873,656
Net operating and investing cash outflows for the period	decreased by	96.59%	to	485,902
Revenue from ordinary activities	increased by	128.49%	to	18,606,356
Revenue and other income	increased by	30.03%	to	28,251,857
Loss from ordinary activities after tax attributable to members	decreased by	56.07%	to	6,863,708

NTA Backing

	<u>2017</u>	<u>2016</u>
Net tangible asset backing per ordinary share	6.9 cents	6.8 cents

Explanation of cash and cash equivalents position as at 30 June 2017:

The closing cash and cash equivalents position is in line with expectations and reflects the Company's continued investment in research and development.

Explanation of net movement in operating and investing cash outflows:

The net movement includes ongoing core R&D expenditure on the Company's clinical programs BNC210 and BNC101 in 2017 and the continued development of the product pipeline. Receipts from customers reflect the US\$10m licensing fee received from Merck (known as MSD outside the USA & Canada), contract services and sales of libraries by our wholly-owned subsidiaries Neurofit and Prestwick.

Explanation of revenue from ordinary activities:

Revenue consists of payments under Bionomics' agreement with MSD, licensing fees received from MSD, contract service revenue of Bionomics' wholly-owned subsidiaries Neurofit and Prestwick, rental and interest income received as a result of ordinary activities and other income including the government's R&D Tax Incentive in Australia and similar incentives for the subsidiaries.

Explanation of net profit from ordinary activities after tax:

The reduced current year loss reflects the Company's investment in research and development activities and its successful commercialisation of its assets.

Dividends/Distributions

Bionomics Limited does not propose to pay any dividend for the year ended 30 June 2017.

ASX ANNOUNCEMENT
16 August 2017

BIONOMICS REPORTS FULL YEAR FINANCIAL RESULTS

Adelaide, Australia: Bionomics Limited (ASX:BNO, OTCQX:BNOEF), today announced its financial results for the 12 months to 30 June 2017.

Clinical Development and Operational Highlights

- BNC210 made strong progress in the clinic reporting positive Phase 2 clinical trial results in a Generalized Anxiety Disorder (GAD) patient population and the initiation of a Phase 2 clinical trial in patients with Post-Traumatic Stress Disorder (PTSD).
- The first administration of a candidate therapy in a clinical trial in February 2017 triggered a US\$10 million milestone payment under our 2014 agreement with MSD (known as Merck & Co., Inc., Kenilworth NJ, USA in the US and Canada). Bionomics previously received US\$20 million in an upfront payment and is eligible to receive up to US\$506 million for reaching pre-defined research and clinical development milestones. In addition, our agreement includes eventual undisclosed royalties on product sales.
- Bionomics' clinical stage oncology assets continued to make progress during the year. In particular, the BNC101 Phase 1 clinical trial in patients with advanced, metastatic colon cancer reached its recommended Phase 2 dose level of 15mg/kg without evidence of dose limiting toxicities or other significant safety issues. With identification of the recommended Phase 2 dose level, the Company initiated enrolment of the final expansion cohort of the study.
- As part of a strategic review, management and Board reached a decision to focus on our essential operations in Australia and France and to close our US operations. The implementation of this decision resulted in significant savings and operational efficiencies.

Key Points – Financial

- Cash at 30 June 2017 was \$42,873,656, a decrease of \$2,576,726 over the 30 June 2016 balance. This balance places the company in strong position to continue to execute its strategy moving forward.
- Revenue and other income for the period was \$28,251,857, compared with \$21,727,915 for the period to 30 June 2016. Revenue growth reflects receipt of a milestone payment.
- The reduced operating loss after tax of the Group for the period was \$6,863,708 and reflects the Company's continued execution of its business plan, including commercialisation of its assets.

- Net operating and investments cash outflows reduced significantly to \$485,902 which highlights the prudent management of the company's cash reserves.

Outlook

Bionomics, with its strong balance sheet, continues to be in an excellent position to progress its development of BNC210 in PTSD and the Company continues to focus on its important relationship with MSD.

As the Company matures, its strategy will focus on its core strength and an area of significant competitive advantage in ion channel biology and drug discovery. In pursuing this path there is a recognition that our clinical stage oncology assets BNC105 and BNC101 are no longer "on strategy". Bionomics will therefore seek to monetise both assets in parallel with its currently committed support of investigator initiated clinical trials funded by granting bodies and Pharma companies.

Consistent with its strategy, Bionomics will seek further opportunities to execute additional partnerships for assets across its portfolio of drug candidates.

FOR FURTHER INFORMATION PLEASE CONTACT:

DR DEBORAH RATHJEN
CEO & MANAGING DIRECTOR
BIONOMICS LIMITED
Ph: +61 8 8354 6101

MR STEVE LYDEAMORE
CFO
BIONOMICS LIMITED
Ph: + 61 8 8354 6100

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.